株探米国株
エドガーで原本を確認する
0001606757false00016067572026-05-052026-05-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)   May 5, 2026
keilogoonelinecolorcmyk2revi.jpg
KIMBALL ELECTRONICS, INC.
________________________________________________________________________________________________________
(Exact name of registrant as specified in its charter)
     
Indiana 001-36454 35-2047713
(State or other jurisdiction of (Commission File (IRS Employer Identification No.)
incorporation) Number)  
     
1205 Kimball Boulevard, Jasper, Indiana
  47546
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code   (812) 634-4000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class Trading Symbol Name of each exchange on which registered
Common Stock, no par value KE The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.02 Results of Operations and Financial Condition
On May 5, 2026, the Company issued an earnings release for the third quarter ended March 31, 2026. The earnings release is attached as Exhibit 99.1.
The information in Item 2.02 of this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit  
Number Description
99.1
104 Cover Page Interactive Data File (formatted in Inline XBRL)

2


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
   
  KIMBALL ELECTRONICS, INC.
   
By: /s/ Jana T. Croom
  JANA T. CROOM
Chief Financial Officer
Date: May 5, 2026

3
EX-99.1 2 exhibit9918k3312026q310q.htm KIMBALL ELECTRONICS, INC. EX-99.1 Document





Exhibit 99.1
releaseheadinglogo.jpg
KIMBALL ELECTRONICS REPORTS Q3 RESULTS
WITH DOUBLE-DIGIT SEQUENTIAL MEDICAL SALES GROWTH; COMPANY AFFIRMS GUIDANCE FOR FISCAL 2026 WITH ADJUSTED OPERATING MARGIN EXPECTED AT HIGH END OF RANGE

JASPER, Ind., May 5, 2026 -- (BUSINESS WIRE) -- Kimball Electronics, Inc. (Nasdaq: KE) today announced financial results for the third quarter ended March 31, 2026.
“Results for the third quarter were in line with expectations. Sales increased sequentially compared to Q2, driven by strong growth in our medical vertical market, margins remained solid, and cash from operations was positive for the ninth consecutive quarter. We expect Q4 to be a good finish to the year and we are affirming our guidance for fiscal 2026 with adjusted operating margin estimated to be at the high end of the range.

As we look forward, the medical CMO continues to be a key part of our strategy and we are making deliberate investments in our capabilities, operating capacity, and commercial focus. When volumes ramp, we expect it to become a meaningful driver of both top line growth and margin expansion. In addition, we continue to focus on inorganic growth as a possible complement to this strategy. We believe this could be a powerful combination for the future of our Company.”

Richard D. Phillips
Chief Executive Officer
  Third Quarter 2026 Highlights
•Revenue of $352.9 million, a sequential increase of 3.4% compared to Q2
•Sales in the medical vertical increased 10.2% versus the prior quarter
•Operating income of $11.8 million, or 3.3% of net sales, adjusted operating margin of 4.2%
•Cash from operations of $14.9 million, the ninth consecutive quarter of positive operating cash generation
•Debt of $163.0 million and borrowing capacity of $276.0 million
•Cash Conversion Days of 90, an improvement compared to both the prior quarter and Q3 of fiscal 2025
•Invested $4.0 million to repurchase 165,000 shares of common stock
•Company affirms guidance for fiscal 2026 with adjusted operating margin expected at the high end of the range As part of today’s announcement, the Company affirmed its guidance for fiscal year 2026.







Net Sales by Vertical Market For Q3 Fiscal 2026
Sales in the automotive vertical market decreased 3% compared to the third quarter of fiscal 2025, while sales in medical and industrial each decreased 8%. As a reminder, in the third quarter of fiscal 2025, the Company reported a non-recurring sale of consigned medical inventory totaling $24 million, or 21% of medical sales in that quarter.
netsalesq326.jpg
*
Percentage of net sales.
**
Percentage changes compared to Q3 of fiscal 2025.
FISCAL YEAR 2026 GUIDANCE
•Net sales in the range of $1,400 - $1,460 million
•Adjusted operating income is estimated to be 4.2% - 4.5% of net sales, with results expected at the high end of the range
•Capital expenditures of $50 - $60 million







webcastq326.jpg
Conference Call / Webcast

Wednesday, May 6, 2026

Live Webcast:
investors.kimballelectronics.com/events-and-presentations/events

For those unable to participate in the live webcast, the call will be archived at investors.kimballelectronics.com.
Forward-Looking Statements
Certain statements contained within this release are considered forward-looking, including our guidance, under the Private Securities Litigation Reform Act of 1995. The statements may be identified by the use of words such as “expect,” “should,” “goal,” “predict,” “will,” “future,” “optimistic,” “confident,” and “believe.” Undue reliance should not be placed on these forward-looking statements. These statements are based on current expectations of future events and thus are inherently subject to uncertainty. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. These forward-looking statements are subject to risks and uncertainties including, without limitation, global economic conditions, geopolitical environment and conflicts such as war, global health emergencies, availability or cost of raw materials and components, tariffs and other trade barriers, foreign exchange rate fluctuations, and our ability to convert new business opportunities into customers and revenue. Additional cautionary statements regarding other risk factors that could have an effect on the future performance of the company are contained in its Annual Report on Form 10-K for the year ended June 30, 2025.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures. The non-GAAP financial measures contained herein include constant currency growth, net sales excluding Automation, Test & Measurement, adjusted selling and administrative expenses, adjusted operating income, adjusted net income, adjusted diluted EPS, and ROIC. Reconciliations of the reported GAAP numbers to these non-GAAP financial measures are included in the Reconciliation of Non-GAAP Financial Measures section below. Management believes these measures are useful and allow investors to meaningfully trend, analyze, and benchmark the performance of the company’s core operations. The company’s non-GAAP financial measures are not necessarily comparable to non-GAAP information used by other companies.
About Kimball Electronics, Inc.
Kimball Electronics is a global, multifaceted manufacturer offering Electronics Manufacturing Services (EMS) and Contract Manufacturing Organization (CMO) solutions to customers around the world. From our operations in the United States, China, Mexico, Poland, Romania, and Thailand, our teams are proud to provide manufacturing services for a variety of industries. Recognized for a reputation of excellence, we are committed to a high-performance culture that values quality, reliability, value, speed, and ethical behavior. Kimball Electronics, Inc. (Nasdaq: KE) is headquartered in Jasper, Indiana.
To learn more about Kimball Electronics, visit www.kimballelectronics.com.
Lasting relationships. Global success.
releaseheadinglogo.jpg
Contact:
Andrew D. Regrut
Vice President, Investor Relations, Strategic Development, and Treasurer
812.827.4151
Investor.Relations@kimballelectronics.com







Financial highlights for the third quarter and year-to-date period ended March 31, 2026 are as follows:
Three Months Ended
Nine Months Ended
March 31, March 31,
(Amounts in Thousands, except EPS) 2026 2025 2026 2025
Net Sales $ 352,922  $ 374,607  $ 1,059,805  $ 1,106,255 
Operating Income
$ 11,755  $ 11,716  $ 36,976  $ 29,061 
Adjusted Operating Income (non-GAAP)
$ 14,781  $ 15,706  $ 47,623  $ 41,629 
Operating Income % 3.3 % 3.1 % 3.5 % 2.6 %
Adjusted Operating Income (non-GAAP) % 4.2 % 4.2 % 4.5 % 3.8 %
Net Income $ 5,719  $ 3,817  $ 19,442  $ 10,403 
Adjusted Net Income (non-GAAP)
$ 8,033  $ 6,837  $ 27,208  $ 19,718 
Diluted EPS
$ 0.23  $ 0.15  $ 0.78  $ 0.41 
Adjusted Diluted EPS (non-GAAP)
$ 0.33  $ 0.27  $ 1.10  $ 0.79 


Net Sales by Vertical Market for Q3 Fiscal 2026:
Three Months Ended
Nine Months Ended
March 31, March 31,
(Amounts in Millions)
2026
*
2025 (2)
* Percent
Change
2026
*
2025 (2)
* Percent Change
Automotive
$ 160.5  46 % $ 165.5  44 % (3) % $ 487.2  46 % $ 533.7  48 % (9) %
Medical
106.1  30 % 115.2  31 % (8) % 304.0  29 % 288.9  26 % 5 %
Industrial excluding AT&M (1)
86.3  24 % 93.9  25 % (8) % 268.6  25 % 281.6  26 % (5) %
Net Sales excluding AT&M (1)
$ 352.9  100 % $ 374.6  100 % (6) % $ 1,059.8  100 % $ 1,104.2  100 % (4) %
AT&M (1)
—  % —  % % —  % 2.1  % (100) %
    Total Net Sales $ 352.9  100 % $ 374.6  100 % (6) % $ 1,059.8  100 % $ 1,106.3  100 % (4) %
*As a percent of Total Net Sales
(1)Sales from our Automation, Test, and Measurement business (AT&M), which was divested effective July 31, 2024, were previously included in the industrial vertical
(2)In the third quarter of fiscal 2025, the Company reported a non-recurring sale of consigned medical inventory totaling $24 million, or 21% of medical sales in that quarter. In addition, beginning in the first quarter of fiscal year 2026, sales to customers related to commercial transportation, previously included in the automotive vertical, are now reflected in the industrial vertical; prior periods have been recast to conform to current period presentation
–Automotive includes electronic power steering, body controls, advanced driver-assistance systems, and electronic braking systems
–Medical includes sleep therapy and respiratory care, image guided therapy, in vitro diagnostics, drug delivery, AED, and patient monitoring
–Industrial includes climate controls, automation controls, public safety, IoT and factory automation, efficient energy, off highway equipment, and commercial transportation








Condensed Consolidated Statements of Income
(Unaudited) Three Months Ended
(Amounts in Thousands, except Per Share Data) March 31, 2026 March 31, 2025
Net Sales $ 352,922  100.0 % $ 374,607  100.0 %
Cost of Sales 325,107  92.1 % 347,711  92.8 %
Gross Profit 27,815  7.9 % 26,896  7.2 %
Selling and Administrative Expenses 15,214  4.4 % 13,154  3.6 %
Restructuring Expense 850  0.2 % 2,026  0.5 %
Asset Impairment
(4) % —  %
Operating Income
11,755  3.3 % 11,716  3.1 %
Interest Income 203  0.1 % 100  %
Interest Expense (2,072) (0.6) % (2,936) (0.8) %
Non-Operating Income (Expense), net (1,099) (0.3) % (1,726) (0.4) %
Other Income (Expense), net (2,968) (0.8) % (4,562) (1.2) %
Income Before Taxes on Income 8,787  2.5 % 7,154  1.9 %
Provision (Benefit) for Income Taxes 3,068  0.9 % 3,337  0.9 %
Net Income
$ 5,719  1.6 % $ 3,817  1.0 %
Earnings Per Share of Common Stock:
Basic $ 0.23  $ 0.15 
Diluted $ 0.23  $ 0.15 
Average Number of Shares Outstanding:
     Basic 24,469  24,728 
     Diluted 24,648  24,872 
(Unaudited) Nine Months Ended
(Amounts in Thousands, except Per Share Data) March 31, 2026 March 31, 2025
Net Sales $ 1,059,805  100.0 % $ 1,106,255  100.0 %
Cost of Sales 975,286  92.0 % 1,032,332  93.3 %
Gross Profit 84,519  8.0 % 73,923  6.7 %
Selling and Administrative Expenses 43,166  4.1 % 37,107  3.4 %
Restructuring Expense 4,083  0.4 % 9,019  0.8 %
Asset Impairment (Gain on Disposal) 294  % (1,264) (0.1) %
Operating Income 36,976  3.5 % 29,061  2.6 %
Interest Income 717  0.1 % 575  0.1 %
Interest Expense (6,520) (0.6) % (11,969) (1.1) %
Non-Operating Income (Expense), net (4,403) (0.5) % (4,155) (0.4) %
Other Income (Expense), net (10,206) (1.0) % (15,549) (1.4) %
Income Before Taxes on Income 26,770  2.5 % 13,512  1.2 %
Provision (Benefit) for Income Taxes
7,328  0.7 % 3,109  0.3 %
Net Income $ 19,442  1.8 % $ 10,403  0.9 %
Earnings Per Share of Common Stock:
Basic $ 0.79  $ 0.42 
Diluted $ 0.78  $ 0.41 
Average Number of Shares Outstanding:
     Basic 24,559  24,859 
     Diluted 24,822  25,047 







Condensed Consolidated Statements of Cash Flows Nine Months Ended
(Unaudited) March 31,
(Amounts in Thousands) 2026 2025
Net Cash Flow provided by Operating Activities $ 29,837  $ 105,870 
Net Cash Flow used for Investing Activities
(38,090) (5,160)
Net Cash Flow provided by (used for) Financing Activities
2,455  (126,615)
Effect of Exchange Rate Change on Cash, Cash Equivalents, and Restricted Cash 540  13 
Net Decrease in Cash, Cash Equivalents, and Restricted Cash
(5,258) (25,892)
Cash, Cash Equivalents, and Restricted Cash at Beginning of Period 89,467  78,779 
Cash, Cash Equivalents, and Restricted Cash at End of Period $ 84,209  $ 52,887 



(Unaudited)
Condensed Consolidated Balance Sheets March 31,
2026
June 30,
2025
(Amounts in Thousands)
ASSETS
    Cash and cash equivalents $ 82,462  $ 88,781 
    Receivables, net 225,983  222,623 
    Contract assets 75,711  71,812 
    Inventories 273,251  273,500 
    Prepaid expenses and other current assets 43,351  36,027 
    Assets held for sale 6,610  6,861 
    Property and Equipment, net 274,937  264,804 
    Goodwill 6,191  6,191 
    Other Intangible Assets, net 2,039  2,427 
    Other Assets, net
113,770  104,286 
        Total Assets $ 1,104,305  $ 1,077,312 
LIABILITIES AND SHARE OWNERS’ EQUITY
    Current portion of long-term debt $ 34,682  $ 17,400 
    Accounts payable 229,068  218,805 
    Advances from customers 18,590  35,867 
    Accrued expenses 53,178  46,489 
    Long-term debt, less current portion 127,850  129,650 
    Other long-term liabilities 63,295  59,217 
    Share Owners’ Equity 577,642  569,884 
        Total Liabilities and Share Owners’ Equity $ 1,104,305  $ 1,077,312 









Other Financial Metrics
(Unaudited)
(Amounts in Millions, except CCD)
At or For the
Three Months Ended
March 31, December 31, March 31,
2026 2025 2025
Depreciation and Amortization $ 10.3  $ 9.3  $ 9.2 
Cash Conversion Days (CCD) (1)
90  91  99 
Open Orders (2)
$ 602  $ 557  $ 642 
(1)Cash Conversion Days (“CCD”) are calculated as the sum of Days Sales Outstanding plus Contract Asset Days plus Production Days Supply on Hand less Accounts Payable Days and less Advances from Customers Days. CCD, or a similar metric, is used in our industry and by our management to measure the efficiency of managing working capital.
(2)Open Orders are the aggregate sales price of production pursuant to unfulfilled customer orders.
Select Financial Results of Automation, Test and Measurement
(Unaudited)
(Amounts in Millions)
Three Months Ended Nine Months Ended
March 31, March 31,
2026 2025 2026 2025
Net Sales $ —  $ —  $ —  $ 2.1 
Operating Income (Loss) (1)
$ —  $ —  $ (0.4) $ 0.8 
(1)Amounts include gain (loss) on sale adjustments following the close of the sale on July 31, 2024: ($0.4 million) in the nine months ended March 31, 2026 and $1.3 million for the nine months ended March 31, 2025.



Reconciliation of Non-GAAP Financial Measures
(Unaudited, Amounts in Thousands, except Per Share Data)
Three Months Ended Nine Months Ended
March 31, March 31,
2026 2025 2026 2025
Net Sales Growth (vs. same period in prior year) (6) % (12) % (4) % (14) %
Foreign Currency Exchange Impact 3 % (1) % 2 % %
Constant Currency Growth (9) % (11) % (6) % (14) %
Selling and Administrative Expenses, as reported $ 15,214  $ 13,154  $ 43,166  $ 37,107 
Stock Compensation Expense (2,256) (1,955) (6,036) (4,528)
SERP 76  (9) (234) (285)
Adjusted Selling and Administrative Expenses $ 13,034  $ 11,190  $ 36,896  $ 32,294 
Operating Income, as reported
$ 11,755  $ 11,716  $ 36,976  $ 29,061 
Stock Compensation Expense 2,256  1,955  6,036  4,528 
SERP (76) 234  285 
Restructuring Expense 850  2,026  4,083  9,019 
Asset Impairment (Gain on Disposal) (4) —  294  (1,264)
Adjusted Operating Income $ 14,781  $ 15,706  $ 47,623  $ 41,629 
Net Income, as reported
$ 5,719  $ 3,817  $ 19,442  $ 10,403 
Stock Compensation Expense, After-Tax 1,711  1,483  4,577  3,434 
Restructuring Expense, After-Tax 606  1,537  2,966  6,840 
Asset Impairment (Gain on Disposal), After-Tax (3) —  223  (959)
Adjusted Net Income $ 8,033  $ 6,837  $ 27,208  $ 19,718 
Diluted Earnings per Share, as reported $ 0.23  $ 0.15  $ 0.78  $ 0.41 
Stock Compensation Expense 0.07  0.06  0.19  0.14 
Restructuring Expense 0.03  0.06  0.12  0.27 
Asset Impairment (Gain on Disposal) —  —  0.01  (0.03)
Adjusted Diluted Earnings per Share $ 0.33  $ 0.27  $ 1.10  $ 0.79 
Twelve Months Ended
March 31,
2026 2025
Operating Income, as reported
$ 53,450  $ 48,669 
SERP 563  381 
Restructuring Expense 6,054  9,783 
Asset Impairment (Gain on Disposal) (833) (788)
Stock Compensation Expense 8,027  6,278 
Adjusted Operating Income
$ 67,261  $ 64,323 
Tax Effect 20,770  20,174 
After-tax Adjusted Operating Income $ 46,491  $ 44,149 
Average Invested Capital (1)
$ 650,994  $ 726,208 
ROIC 7.1 % 6.1 %
(1) Average invested capital is computed using Share Owners’ equity plus current and non-current debt less cash and cash equivalents averaged for the last five quarters.